IP Library Granted Patent US 11,950,903
Granted Patent B2
US 11,950,903 · App. 16/191,913 · Granted Apr 9, 2024

Reporting of glycemic variability from continuous glucose monitoring

Inventors: James Masciotti (Germantown, MD); Barbara Montgomery (Gaithersburg, MD)
Assignee: Senseonics, Incorporated
A61B5/14532A61B5/0004A61B5/7435G16H50/30A61B5/4842A61B5/6801A61B5/743A61B5/746A61B5/7465G16H10/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,950,903
App. No.
16/191,913
Granted
Apr 9, 2024
Kind
B2
Abstract

In one aspect, a method of estimating an HbA1c level is provided. The method may include obtaining a first and second glucose measurement, adding the first and the second glucose measurements to a glucose measurement data set, and calculating an estimated HbA1c level using at least the glucose measurement data set. In another aspect, a method of calculating a range of an estimated HbA 1c level is provided. The method may comprise at least calculating an estimated HbA 1c level and a standard deviation of the estimated HbA 1c level using a glucose measurement data set, and combining the estimated HbA 1c level with the standard deviation of the estimated HbA 1c level to acquire the range of the estimated HbA 1c level. In another aspect, a glucose monitoring device may display glycemic variability of an individual.

Claims (188)

1. An analyte monitoring method comprising:

using an analyte monitoring sensor of an analyte monitoring system to measure glucose levels of a patient, wherein using the analyte monitoring sensor of the analyte monitoring system to measure the glucose levels of the patient comprises using a fluorometer of the analyte monitoring sensor to measure the glucose levels of the patient, using the fluorometer of the analyte monitoring sensor to measure the glucose levels of the patient comprises using the fluorometer to measure parameters of fluorescence after and/or during excitation by a spectrum of light, and the measured parameters include an intensity and/or a wavelength distribution of emission spectrum of the fluorescence;

using the analyte monitoring sensor to communicate over a wireless communication link;

using an analyte monitoring device of the analyte monitoring system to obtain a first glucose measurement indicative of a first glucose level of the patient;

using the analyte monitoring device to obtain a second glucose measurement indicative of a second glucose level of the patient;

using the analyte monitoring device to add the first and the second glucose measurements to a glucose measurement data set;

using a processor of the analyte monitoring device to calculate an estimated HbA 1c level using the glucose measurement data set, an association constant k 2 , and an association constant k 3 , wherein the association constant k 2 represents a conversion of a pre-A 1c to an HbA 1c , and the association constant k 3 represents a life span of the pre-A 1c and the HbA 1c ; and

using a display of the analyte monitoring device to display the estimated HbA 1c level.

2. The method of claim 1 , wherein calculating the estimated HbA 1c level comprises taking a convolution of a first function and a second function, wherein the first function includes the glucose measurement data set, and the second function includes the association constant k 2 and the association constant k 3 .

3. The method of claim 2 , wherein the first function further includes an association constant K eq that represents an equilibrium constant of glucose.

4. The method of claim 2 , wherein the second function further includes an association constant k 1 and an association constant k −1 , the association constant k 1 represents a binding constant when a glucose attaches to a hemoglobin to form the pre-A 1c , and the association constant k −1 represents a dissociation constant when the glucose detaches from the hemoglobin.

5. The method of claim 1 , further comprising:

using the analyte monitoring device to receive a blood HbA 1c measurement; and

using the analyte monitoring device to calibrate one or more of the first and second functions using the received blood HbA 1c measurement.

6. The method of claim 5 , wherein calibrating the one or more of the first and second functions comprises:

adjusting one or more of the association constant k 2 , the association constant k 3 , the association constant K eq , the association constant k 1 , and the association constant k −1 .

7. The method of claim 1 , wherein the glucose levels are interstitial fluid glucose levels.

8. The method of claim 1 , further comprising employing the measured parameters to identify a presence and/or an amount of specific molecules in a medium.

9. The method of claim 1 , wherein the analyte monitoring sensor is an implantable sensor inserted subcutaneously inside the patient.

10. The method of claim 1 , wherein the analyte monitoring system obtains the first and second glucose measurements directly from the analyte monitoring sensor.

11. The method of claim 1 , wherein the analyte monitoring system obtains the first and second glucose measurements from a transceiver of the analyte monitoring system.

12. The method of claim 1 , further comprising using a transceiver of the analyte monitoring system to receive the measured parameters from the analyte monitoring sensor, wherein the analyte monitoring device obtains the first and second glucose measurements from the transceiver.

13. The method of claim 1 , further comprising:

using the processor of the analyte monitoring device to calculate a standard deviation of the estimated HbA 1c level using the glucose measurement data set;

using the processor of the analyte monitoring device to combine the estimated HbA 1c level with the standard deviation of the estimated HbA 1c level to acquire a range of the estimated HbA 1c level; and

using a display of the analyte monitoring device to display the range of the estimated HbA 1c level.

14. The method of claim 1 , wherein the processor of the analyte monitoring device uses the following formula to calculate the estimated HbA 1c level:

[

H

b

A

1

c

]

[

H

b

]

(

mmol

mol

)

=

[

G

L

U

]

(

t

)

*

(

k

1

k

2

k

-

1

+

k

2

(

e

-

k

3

t

-

e

-

(

k

3

+

k

-

1

+

k

2

)

t

)

)

,

where k 1 is an association constant that represents a binding constant when a glucose attaches to a hemoglobin to form the pre-A 1c , and k −1 is an association constant that represents a dissociation constant when the glucose detaches from the hemoglobin.

15. An analyte monitoring method comprising:

using an analyte monitoring sensor of an analyte monitoring system to measure glucose levels of a patient, wherein using the analyte monitoring sensor of the analyte monitoring system to measure the glucose levels of the patient comprises using a fluorometer of the analyte monitoring sensor to measure the glucose levels of the patient, using the fluorometer of the analyte monitoring sensor to measure the glucose levels of the patient comprises using the fluorometer to measure parameters of fluorescence after and/or during excitation by a spectrum of light, and the measured parameters include an intensity and/or a wavelength distribution of emission spectrum of the fluorescence;

using the analyte monitoring sensor to communicate over a wireless communication link;

using an analyte monitoring device of the analyte monitoring system to obtain a first glucose measurement indicative of a first glucose level of the patient;

using the analyte monitoring device to obtain a second glucose measurement indicative of a second glucose level of the patient;

using the analyte monitoring device to add the first and the second glucose measurements to a glucose measurement data set;

using a processor of the analyte monitoring device to calculate an estimated HbA 1c level using the glucose measurement data set and the following formula:

[

H

b

A

1

c

]

[

H

b

]

(

mmol

mol

)

=

[

G

L

U

]

(

t

)

*

(

k

1

k

2

k

-

1

+

k

2

(

e

-

k

3

t

-

e

-

(

k

3

+

k

-

1

+

k

2

)

t

)

)

where k 1 is an association constant that represents a binding constant when a glucose attaches to a hemoglobin to form a pre-A 1c , k −1 is an association constant that represents a dissociation constant when the glucose detaches from the hemoglobin, k 2 is an association constant that represents a conversion of the pre-A 1c to an HbA 1c and k 3 is an association constant that represents a life span of the pre-A 1c and the HbA 1c ;

using the processor of the analyte monitoring device to calculate a standard deviation of the estimated HbA 1c level using the glucose measurement data set;

using the processor of the analyte monitoring device to combine the estimated HbA 1c level with the standard deviation of the estimated HbA 1c level to acquire a range of the estimated HbA 1c level; and

using a display of the analyte monitoring device to display the range of the estimated HbA 1c level.

16. The method of claim 15 , wherein the glucose levels are interstitial fluid glucose levels.

17. The method of claim 15 , further comprising employing the measured parameters to identify a presence and/or an amount of specific molecules in a medium.

18. The method of claim 15 , wherein the analyte monitoring sensor is an implantable sensor inserted subcutaneously inside the patient.

19. The method of claim 15 , wherein the analyte monitoring system obtains the first and second glucose measurements directly from the analyte monitoring sensor.

20. The method of claim 15 , wherein the analyte monitoring system obtains the first and second glucose measurements from a transceiver of the analyte monitoring system.

21. The method of claim 15 , further comprising using a transceiver of the analyte monitoring system to receive the measured parameters from the analyte monitoring sensor, wherein the analyte monitoring device obtains the first and second glucose measurements from the transceiver.

Assignments (10)
SECURITY INTEREST Recorded Sep 11, 2023
From: SENSEONICS, INCORPORATED
To: HERCULES CAPITAL, INC.
Reel/Frame 064866/0963 →
RELEASE OF SECURITY INTEREST Recorded Sep 7, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 064834/0962 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: SENSEONICS HOLDINGS, INC.; SENSEONICS, INCORPORATED
Reel/Frame 063338/0890 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 14, 2020
From: SENSEONICS, INCORPORATED
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 053496/0292 →
RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Aug 14, 2020
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 053498/0275 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT -SECOND LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052490/0160 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - FIRST LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052492/0109 →
RELEASE OF SECURITY INTEREST Recorded Mar 23, 2020
From: SOLAR CAPITAL LTD., AS AGENT
To: SENSEONICS, INCORPORATED
Reel/Frame 052207/0242 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 1, 2019
From: SENSEONICS, INCORPORATED
To: SOLAR CAPITAL LTD., AS AGENT
Reel/Frame 049926/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: MASCIOTTI, JAMES; MONTGOMERY, BARBARA
To: SENSEONICS, INCORPORATED
Reel/Frame 048941/0204 →